THE EFFECT OF EFAVIRENZ AND RITONAVIR-BOOSTED DARUNAVIR ON THE PHARMACOKINETICS OF THE HMG CoA REDUCTASE INHIBITOR PITAVASTATIN

Next Previous
Trial Profile

THE EFFECT OF EFAVIRENZ AND RITONAVIR-BOOSTED DARUNAVIR ON THE PHARMACOKINETICS OF THE HMG CoA REDUCTASE INHIBITOR PITAVASTATIN

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Mar 2013

At a glance

  • Drugs Darunavir (Primary) ; Efavirenz (Primary) ; Pitavastatin (Primary) ; Ritonavir (Primary)
  • Indications Dyslipidaemias; HIV infections; Hypercholesterolaemia; Hyperlipidaemia
  • Focus Pharmacokinetics

    • Most Recent Events

    • 09 Oct 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top